Alkermes(ALKS) Prnewswire·2025-02-12 12:00Financial Performance - Total revenues for 2024 were reported at $1.56 billion, with proprietary product net sales increasing approximately 18% year-over-year [1][3] - GAAP net income from continuing operations was $372 million, translating to diluted GAAP earnings per share of $2.20 for 2024 [1][3] - The company generated over $1 billion in revenue from its proprietary commercial product portfolio and delivered EBITDA from continuing operations of approximately $452 million [2][3] Product Performance - Proprietary net sales for the fourth quarter of 2024 were $307.7 million, compared to $242.0 million in the same quarter of 2023, marking a significant increase [3][12] - Key products included VIVITROL® with revenues of $134.1 million (up 31% year-over-year), ARISTADA® with $96.6 million (up 16%), and LYBALVI® with $77.0 million (up 37%) [3][12] Operational Developments - The company completed the sale of its manufacturing business in Ireland and ended 2024 debt-free with approximately $825 million in cash and investments [2][13] - Ongoing Phase 2 studies for ALKS 2680 in narcolepsy are expected to yield data in the second half of 2025, with plans to initiate additional studies in idiopathic hypersomnia [2][1] Financial Expectations for 2025 - The company anticipates total revenues between $1.34 billion and $1.43 billion for 2025, with specific net sales expectations for VIVITROL, ARISTADA, and LYBALVI [15] - Projected GAAP net income for 2025 is estimated to be between $175 million and $205 million, with EBITDA expected to range from $215 million to $245 million [15][34]